Wegener Granulomatosis
12
0
2
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
8.3%
1 terminated out of 12 trials
87.5%
+1.0% vs benchmark
42%
5 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
Hydroxychloroquine in ANCA Vasculitis Evaluation
Efficacy Study of Two Treatments in the Remission of Vasculitis
TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Rituximab Vasculitis Maintenance Study
Low-dose Glucocorticoid Vasculitis Induction Study
VCRC Patient Contact Registry Patient-Reported Data Validation Study
Journey of Patients With Vasculitis From First Symptom to Diagnosis
Impact of Vasculitis on Employment and Income
PRO Development for ANCA Associated Vasculitis
Vasculitis Illness Perception (VIP) Study
Educational Needs of Patients With Systemic Vasculitis